Clinical trials: Pruritis
Pain, Nausea
Optimal Dose of Prophylactic Naloxone in Reducing Opioid-Induced Side Effects in Children/Adolescents
This is an investigator initiated dose finding study designed to determine the optimal dose of naloxone to prevent or minimize the most common side effects induced by opioids, namely itching, nausea, and vomiting.
- Conditions
- Pain, Nausea, Pruritus
- Trial name
- NCT00330343
- Testing
- naloxone
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Johns Hopkins University
Epidermolysis Bullosa
A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa
To determine if Serlopitant (when taken by mouth) is safe and works on itch in patients aged 13 and above with EB.
- Trial name
- NCT03836001
- Testing
- Serlopitant Tablet
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Stanford University
Atopic Dermatitis
Acupressure in Pruritus for Atopic Dermatitis
The purpose of this study is to see if acupressure will be effective at reducing itch in people with atopic dermatitis (AD).
- Trial name
- NCT01074164
- Testing
- Standard-of-care treatment for AD, Accu-patch pellet
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
Plaque-type Psoriasis
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
The purpose of this study was to demonstrate efficacy of autoinjector administered secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.
- Trial name
- JUNCTURE (NCT01636687)
- Testing
- Secukinumab 150mg, Secukinumab 300mg
- Where
- 39 sites in United States, Canada and 3 more
- Volunteers
- 182 people
- Sponsor
- Novartis Pharmaceuticals
Prurigo Nodularis
Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
The primary objective was to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (>=) 18 years of age with prurigo nodularis (PN) after a 16 week treatment period.
- Trial name
- NCT04501666
- Testing
- Nemolizumab 30 mg
- Where
- 100 sites in United States, Austria and 8 more
- Volunteers
- 286 people
- Sponsor
- Galderma R&D
Atrophic Vaginitis
A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis
The purpose of this study is to determine the therapeutic equivalence of Mylan's estradiol vaginal cream to Estrace® cream and superiority of both products to placebo.
- Trial name
- NCT02195986
- Testing
- Estradiol Vaginal Cream, 0.01%, Estrace® 0.01% cream
- Where
- 21 sites in United States
- Volunteers
- 366 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Trichomonas Infection
A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis
This is a Phase 3, multi-center, prospective, randomized, placebo-controlled, delayed treatment, double-blind, study to evaluate the effectiveness, and safety of a single, oral dose of Solosec® containing 2 grams of secnidazole…
- Trial name
- NCT03935217
- Testing
- Secnidazole
- Where
- 11 sites in United States
- Volunteers
- 147 people
- Sponsor
- Lupin Research Inc